(2R,4S)-N-Alpha-T-Butoxycarbonyl-4-Hydroxypyrrolidine-2-Carbo

When a 50 L glass-lined reactor is charged with 8.2 kg of (2R,4S)-N-Boc-4-hydroxyproline for a liquid-phase fragment condensation en route to a macrocyclic NS3/4A protease inhibitor, the batch record flags a non-negotiable parameter: the free 4S-hydroxyl group lies cis to the carboxylic acid on the pyrrolidine ring and, under standard carbodiimide activation, can form an intramolecular lactone at rates exceeding 2% per hour at 25°C. The process design therefore locks the activation protocol into a pre-cooled mixed anhydride procedure. Isobutyl chloroformate (1.05 eq.) is added dropwise to a solution of the amino acid in anhydrous tetrahydrofuran containing N-methylmorpholine (1.20 eq.) at −15 ± 2°C. After 12 min, the pre-formed anhydride is quenched into a chilled solution of the proline-derived amine nucleophile (0.92 eq., free base) in dichloromethane. Stoichiometric control is decisive: excess nucleophile beyond 1.0 eq. leads to epimerization at the C-2 position, generating the (2S,4S)-diastereomer, detectable by chiral HPLC (Chiralpak IA column, n-hexane/ethanol/0.1% trifluoroacetic acid, 1.0 mL·min⁻¹). Rinse campaigns across three production batches recorded a mean yield of 87.6% with a diastereomeric excess exceeding 99.5%. The work-up requires sequential bicarbonate scrub (to remove residual anhydride degradation products) followed by heptane-induced crystallization at −5°C to isolate the intermediate that is carried directly into a macrocyclization step catalyzed by a Hoveyda–Grubbs second-generation catalyst. Residual solvent limits align with ICH Q3C: tetrahydrofuran ≤ 720 ppm, dichloromethane ≤ 600 ppm, heptane ≤ 5000 ppm. The target compound serves as the P2–P3 junction fragment in a marketed direct-acting antiviral against genotype 1b hepatitis C, and the quality agreement mandates compliance with ICH Q7 for active pharmaceutical ingredient starting materials, supplemented by a dedicated gas chromatography method per USP 〈467〉.

What drives the need for hydroxyl protection in solution-phase amide bond formation using Boc-Hyp-OH? Direct activation of the unprotected hydroxyproline derivative in the presence of a sterically hindered amine frequently yields a complex mixture where the 4-hydroxyl group intercepts the activated ester to form a δ-lactone by-product, consuming up to 12% of the input mass in bench-scale trials. The manufacturing route therefore installs a temporary silyl ether shield. The substrate is dissolved in N,N-dimethylformamide (8.0 L·kg⁻¹) with imidazole (3.0 eq.) and tert-butyldimethylsilyl chloride (1.5 eq.) is added portionwise, maintaining the internal temperature below 10°C. After 16 h, in-process liquid chromatography–mass spectrometry confirms ≥98% conversion to the O-TBS ether. The protected intermediate is extracted into ethyl acetate, washed with 5% citric acid and brine, and concentrated to a foam where residual DMF is kept below 100 ppm as verified by headspace gas chromatography. Coupling with an aminopyridine-fragment (factor Xa inhibitor clinical candidate) employs HATU (1.08 eq.) and 2,4,6-collidine (2.5 eq.) in a mixed solvent of acetonitrile and N-methyl-2-pyrrolidone (9:1, v/v). The reaction is held at −18°C for 25 min, quenched with ice-cold 0.5 M potassium bisulfate, and the organic layer is immediately passed through a plug of silica gel to remove silyl by-products. Deprotection of the O-TBS group with tetra-n-butylammonium fluoride trihydrate (1.25 eq.) in tetrahydrofuran at 0°C regenerates the free hydroxyproline residue that subsequently coordinates to a serine protease active site. The final active pharmaceutical ingredient is recrystallized from isopropanol/water to a polymorphic form validated by PXRD per USP 〈941〉. Compliance to ICH Q3D is evidenced by an inductively coupled plasma mass spectrometry panel showing cumulative Class 1 metal impurities ≤ 1.0 µg/g. Batch documentation is maintained under 21 CFR Part 211 audit trail for a Phase III supply chain.

In the assembly of collagen model peptides of sequence (Pro-Hyp-Gly)₁₀ on a rink amide resin via Fmoc-SPPS, the incorporation of (2R,4S)-N-Boc-4-hydroxyproline as a capping agent immediately after the tenth coupling cycle alters triple-helix thermal stability in a manner not achievable with conventional acetyl or succinyl end groups. After removal of the terminal Fmoc with 20% piperidine in DMF, the peptidyl-resin (substitution 0.28 mmol·g⁻¹) is treated with a pre-activated solution of Boc-Hyp-OH (5.0 eq.), HBTU (4.8 eq.), and 2,4,6-trimethylpyridine (12 eq.) in N-methylpyrrolidone for 2 × 45 min at 22°C. A Kaiser test confirms negative primary amine response. Cleavage is performed with a modified Reagent K cocktail (trifluoroacetic acid/thioanisole/water/phenol/1,2-ethanedithiol at 82.5:5:5:5:2.5, v/v) for 3.5 h. The crude peptide is precipitated in cold diethyl ether, purified by reverse-phase HPLC (C18, 10 µm, 250 × 21.2 mm, gradient 15–45% acetonitrile in 0.1% aqueous TFA), and lyophilized to a white powder. Circular dichroism spectroscopy reveals a melting temperature (T_m) increase from 52°C (acetyl-capped control) to 64°C for the Boc-Hyp-capped variant at 2.0 mg·mL⁻¹ in phosphate-buffered saline, attributed to the extra H-bond network formed by the terminal hydroxyproline moiety. The lyophilized material is formulated into a shear-thinning, photocrosslinkable hydrogel by grafting methacryloyl chloride onto free hydroxyl groups in the peptide core. Cytotoxicity evaluated per ISO 10993-5 extract dilution test on L929 fibroblasts shows no adverse effect up to 100% extract concentration. The resulting scaffold is evaluated as an injectable vitreous substitute in a large-animal model, with in-vivo degradation half-life measured by magnetic resonance imaging contrast decay.

Chiral derivatization agent for enantiomeric excess determination of fluorinated aliphatic primary amines. A critical performance gap in pharmacopoeial impurity profiling occurs when the target amine lacks a chromophore and requires pre-column derivatization to enable UV detection and chiral resolution. (2R,4S)-N-Boc-4-hydroxyproline fills this role after a rapid carboxyl activation protocol. The derivatizing solution is prepared fresh daily by dissolving Boc-Hyp-OH (12.0 mg, 0.052 mmol) in dry dichloromethane (1.0 mL) containing 0.02% v/v pyridine, and adding EDC·HCl (1.5 eq.) and HOBt·H₂O (1.5 eq.) at 0°C. The amine sample (0.04 mmol) is introduced as a dichloromethane solution, and the mixture is stirred at 4°C for 90 min. The reaction is quenched with 0.1 M HCl, washed with saturated sodium bicarbonate, and the organic layer is evaporated to dryness under a nitrogen stream. The diastereomeric amides are reconstituted in mobile phase (acetonitrile/20 mM ammonium formate pH 3.0, 40:60) and separated on a C18 column (150 × 4.6 mm, 3 µm) at 1.0 mL·min⁻¹ and 40°C, with UV detection at 210 nm. Resolution between (R)-amine and (S)-amine derivatives consistently exceeds 3.5, and the limit of quantification for the undesired enantiomer is 0.04% relative to the main peak. The method has been validated in accordance with ICH Q2(R1) specificity, linearity, accuracy, and precision parameters, and the verification protocol adopts USP 〈1225〉 guidelines. The derivatization approach has been incorporated into release testing monographs for an inhaled beta-3 adrenergic receptor agonist active pharmaceutical ingredient, where the acceptable limit for the (R)-enantiomer is set at NMT 1.0%.

When residual palladium limits the use of hydrogenolytic deprotection in protected peptide synthesis. In a convergent synthetic route to a cyclic RGD peptidomimetic designed to inhibit α_vβ₃ integrin, the free hydroxyl of (2R,4S)-N-Boc-4-hydroxyproline is first converted to its benzyl ether to serve as a semi-permanent protecting group that can be cleaved without disturbing the Boc urethane or acid-labile side-chain protections. The benzylation is performed in anhydrous tetrahydrofuran (6.0 L·kg⁻¹) at 0°C by slow addition of sodium hydride (1.3 eq., 60% dispersion in mineral oil) followed by benzyl bromide (1.2 eq.) and a catalytic amount of tetra-n-butylammonium iodide (0.05 eq.). After 18 h at ambient temperature, the mixture is poured onto ice, extracted with ethyl acetate, and the crude O-benzyl ether is purified by flash chromatography (silica gel, hexane/ethyl acetate 3:1) to give a colorless oil that solidifies upon standing. This protected building block is subsequently activated with isobutyl chloroformate and coupled to a lysine-derived fragment as described previously. The key orthogonal deprotection step occurs at the final stage: the assembled linear tripeptide, containing the O-benzyl ether and a tert-butyl ester, is subjected to hydrogenation over 10% palladium on carbon (5% by weight) in ethanol/water (4:1) under 1 atm H₂ for 4 h. The Boc group remains intact throughout, and the catalyst is removed by filtration through a microfilter cloth (0.2 µm). Analysis of the filtrate by inductively coupled plasma optical emission spectroscopy confirms residual palladium content below 10 µg·g⁻¹, meeting the oral permitted daily exposure limit of ICH Q3D. The fully deprotected peptide is cyclized using diphenylphosphoryl azide and sodium bicarbonate in DMF, isolated by semi-preparative HPLC, and lyophilized from 0.1 M hydrochloric acid to obtain the integrin antagonist as the hydrochloride salt. Stability of the final product stored in amber vials at −20°C for 24 months is documented by monthly HPLC purity tests with a specification of ≥ 97.0% main peak and no unknown impurity exceeding 0.5%.